Direct-acting antiviral agents — Competitive Intelligence Brief

Direct-acting antiviral agents (Direct-acting antiviral agents) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral. Area: Infectious Disease.

phase 2 Direct-acting antiviral Viral enzymes or proteins Infectious Disease Small molecule

Target snapshot

Direct-acting antiviral agents (Direct-acting antiviral agents) — Qing XIe. Direct-acting antiviral agents target viral replication by inhibiting viral enzymes or proteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Direct-acting antiviral agents TARGET	Direct-acting antiviral agents	Qing XIe	phase 2	Direct-acting antiviral	Viral enzymes or proteins
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Clinically prescribed direct acting antiviral	Clinically prescribed direct acting antiviral	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA)
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
ABT450r-ABT267-ABT333 +/- Ribavirin	ABT450r-ABT267-ABT333 +/- Ribavirin	Ottawa Hospital Research Institute	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
Glecaprevir and Pibrentasvir	Glecaprevir and Pibrentasvir	Massachusetts General Hospital	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Elbasvir/Grazoprevir	Elbasvir/Grazoprevir	University of Florence	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	HCV NS5A protein and HCV NS3/4A serine protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral class)

1. Hospices Civils de Lyon · 1 drug in this class
2. Iran Hepatitis Network · 1 drug in this class
3. Qing XIe · 1 drug in this class
4. Sang Gyune Kim · 1 drug in this class